Our study not only added to the knowledge of antifibrotic M2 macrophages but, also, provided the bench evidence that pharmacological HDAC inhibitors can be applied to clinical treatments of renal fibrosis in the future. This evidence concerns the gene HDAC9 and renal fibrosis.